Journal List > J Korean Ophthalmol Soc > v.54(11) > 1009534

J Korean Ophthalmol Soc. 2013 Nov;54(11):1700-1707. Korean.
Published online November 15, 2013.  https://doi.org/10.3341/jkos.2013.54.11.1700
Copyright © 2013 The Korean Ophthalmological Society
Twelve-Month Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Retinal Angiomatous Proliferation
Deok Bae Kim, MD,1 Jae Hui Kim, MD,2 Seong Hun Jeong, MD,2 Tae Gon Lee, MD,2 Jong Woo Kim, MD,2 Chul Gu Kim, MD,2 Sung Won Cho, MD,2 Dong Won Lee, MD,2 and Jung Il Han, MD2
1Happyeye21 Hospital, Gwangju, Korea.
2Department of Ophthalmology, Kim's Eye Hospital, Konyang University College of Medicine, Seoul, Korea.

Address reprint requests to Jae Hui Kim, MD. Kim's Eye Hospital, #136 Yeongsin-ro, Yeongdeungpo-gu, Seoul 150-034, Korea. Tel: 82-2-2671-7665, Fax: 82-2-2671-6359, Email: kjh7997@daum.net
Received June 21, 2013; Revised September 07, 2013; Accepted October 28, 2013.

Abstract

Purpose

To evaluate the 12-month outcomes of anti-vascular endothelial growth factor (VEGF) treatment for patients with retinal angiomatous proliferation (RAP).

Methods

Retrospective review of medical records was performed for 33 patients (33 eyes) who were diagnosed with RAP. All patients were initially treated with three consecutive intravitreal anti-VEGF injections after diagnosis. Additional treatment was performed when the recurrence of exudation was noted. The best-corrected visual acuity (BCVA) was measured before the first injection and at 3, 6, and 12 months after the first injection. The value measured before the treatment was compared with those measured after treatment.

Results

The patients received an average of 4.2 ± 1.7 intravitreal anti-VEGF injections during the 12-month follow-up period. The logarithm of minimal angle of resolution (log MAR) values of BCVA before the first injection and at 3, 6, and 12 months after the first injections were 0.76 ± 0.49, 0.55 ± 0.35, 0.67 ± 0.41, and 0.70 ± 0.50, respectively. BCVA was significantly improved at 3 and 6 months (p < 0.001 and p = 0.037) compared to that measured before the first injection. However, there was no significant difference between BCVA before the first injection and 12 months after the first injection (p = 0.590). At 12 months of follow-up, 29 eyes (87.9%) showed stable (<2 log MAR lines of change) or improved (≥2 log MAR lines of improvement) BCVA.

Conclusions

Anti-VEGF therapy was found to be beneficial in both normalizing macular thickness and in improving or maintaining visual acuity in the majority of patients with RAP.

Keywords: Anti-vascular endothelial growth factor; Clinical outcomes; Retinal angiomatous proliferation; Visual acuity

Figures


Figure 1
Central foveal thickness (double-head arrow) was defined as the vertical distance between internal limiting membrane and retinal pigment epithelium at foveal center based on optical coherence tomography image centered at the center of the fovea.
Click for larger image


Figure 2
Fundus photography (A), indocyanine green angiography (B), and optical coherence tomography (C) images in an eye with retinal angiomatous proliferation. Arrow (B) on indocyanine green angiography image indicates retinal angiomatous proliferation lesion. Optical coherence tomography images showing macular microstructure before treatment (C1) and 3 months (C2), 8 months (C3), and 12 months (C4) after the first intravitreal anti-vascular endothelial growth factor injection. Recurrence of exudation was noted at 8 months following the first treatment. The best-corrected visual acuity measured before treatment was 20/40. The visual acuity was improved to 20/30 after three monthly injections, but deteriorated to 20/60 after the recurrence of exudation. At 12-month after the first treatment, the visual acuity was measured as 20/40.
Click for larger image


Figure 3
Twelve-month changes in logarithm of minimal angle of resolution (log MAR) best-corrected visual acuity (A, BCVA) and central foveal thickness (B) in eyes with retinal angiomatous proliferation that were treated with anti-vascular growth factor mono-treatment, according to the follow-up period. Statistical analysis was performed using repeated measures analysis of variances.
Click for larger image


Figure 4
(A-D) Baseline fundus photography (A), fluorescein angiography (B), indocyanine green angiography (C), and optical coherence tomography (D) findings of an eye with retinal angiomatous proliferation. (E-G) Twelve months after anti-vascular endothelial growth factor treatment, resolution of retinal hemorrhage (E) cessation of leakage (F) and resolution of intraretinal and subretinal fluid (G) was noted. The visual acuity was improved from 20/400 to 20/100.
Click for larger image

Tables


Table 1
Characteristics of 33 included eyes (33 patients) with retinal angiomatous proliferation
Click for larger image


Table 2
Distribution of eyes according to the degree of visual acuity change between at diagnosis and at 12-month following the first anti-vascular endothelial growth factor injection (N = 33)
Click for larger image

References
1. Yannuzzi LA, Negrão S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416–434.
2. Massacesi AL, Sacchi L, Bergamini F, Bottoni F. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008;246:89–92.
3. Maruko I, Iida T, Saito M, et al. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 2007;144:15–22.e2.
4. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular age-related macular degeneration in Chinese patients. Graefes Arch Clin Exp Ophthalmol 2007;245:1441–1445.
5. Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25:713–718.
6. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch Ophthalmol 2005;123:1644–1650.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
8. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432–1444.
9. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006;26:383–390.
10. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409–413.e1.
11. Kang S, Cho WK, Roh YJ. The efficacy of ranibizumab for choroidal neovascularization in age-related macular degeneration. J Korean Ophthalmol Soc 2009;50:725–730.
12. Kim YH, Kim ES, Yu SY, Kwak HW. Long-term effect of intravitreal bevacizumab for CNV secondary to age-related macular degeneration. J Korean Ophthalmol Soc 2008;49:1935–1940.
13. Parodi MB, Iacono P, Menchini F, et al. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation. Acta Ophthalmol 2013;91:267–273.
14. Ghazi NG, Knape RM, Kirk TQ, et al. Intravitreal bevacizumab (Avastin) treatment of retinal angiomatous proliferation. Retina 2008;28:689–695.
15. Konstantinidis L, Mameletzi E, Mantel I, et al. Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol 2009;247:1165–1171.
16. Costagliola C, Romano MR, dell'Omo R, et al. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol 2007;144:449–451.
17. Hufendiek K, Hufendiek K, Panagakis G, et al. Visual and morphological outcomes of bevacizumab (Avastin®) versus ranibizumab (Lucentis®) treatment for retinal angiomatous proliferation. Int Ophthalmol 2012;32:259–268.
18. Kang JH, Park KA, Chung SE, Kang SW. Retinal angiomatous proliferation and intravitreal bevacizumab injection. Korean J Ophthalmol 2007;21:213–215.
19. Lee MY, Kim KS, Lee WK. Combination therapy of ranibizumab and photodynamic therapy for retinal angiomatous proliferation with serous pigment epithelial detachment in Korean patients:twelve-month results. Retina 2011;31:65–73.
20. Lee PY, Lee WK. Treatments of stage 1 retinal angiomatous proliferation. J Korean Ophthalmol Soc 2008;49:442–449.
21. Byeon SH, Hong JP, Lee H, et al. Photodynamic therapy results of retinal angiomatous proliferation with pigmented epithelial detachment in age-related macular degeneration. J Korean Ophthalmol Soc 2006;47:1410–1416.
22. Cho YJ, Park SP. Intravitreal ranibizumab therapy for neovascular age-related macular degeneration with a predominantly hemorrhagic lesion. J Korean Ophthalmol Soc 2011;52:838–845.
23. Chang MA, Do DV, Bressler SB, et al. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina 2010;30:1171–1176.
24. Shienbaum G, Garcia Filho CA, Flynn HW Jr, et al. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti-vascular endothelial growth factor monotherapy. Am J Ophthalmol 2013;155:1009–1013.
25. Avery RL, Fekrat S, Hawkins BS, Bressler NM. Natural history of subfoveal subretinal hemorrhage in agerelated macular degeneration. Retina 1996;16:183–189.
26. Bennett SR, Folk JC, Blodi CF, Klugman M. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990;109:33–37.
27. Riusala AM, Immonen IJ. Predictors of structural findings in old disciform lesions. Am J Ophthalmol 2004;138:245–253.
28. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287–290.
29. Arias L, Armada F, Donate J, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye (Lond) 2009;23:326–333.
30. Oliver-Fernandez A, Bakal J, Segal S, et al. Progression of visual loss and time between initial assessment and treatment of wet age-related macular degeneration. Can J Ophthalmol 2005;40:313–319.
31. Rauch R, Weingessel B, Maca SM, Vecsei-Marlovits PV. Time to first treatment: the significance of early treatment of exudative age-related macular degeneration. Retina 2012;32:1260–1264.